<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Age-related differences in the distribution, biology and treatment response of non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) in adolescents remain to be elucidated </plain></SENT>
<SENT sid="1" pm="."><plain>The current analyses present clinical parameters and outcomes of adolescents treated in <z:e sem="disease" ids="C0220612" disease_type="Neoplastic Process" abbrv="">pediatric NHL</z:e>-BFM trials </plain></SENT>
<SENT sid="2" pm="."><plain>Patients were stratified by histological subtype: lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (LBL); mature B-NHL, including Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>/B-AL), diffuse B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>-CB) and mediastinal B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (PMLBL); and anaplastic large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALCL</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>Between October 1986 and December 2007, 2915 patients were registered, including 378 (13%) adolescents (15-18 years) with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>/B-AL (n=101), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALCL</z:e> (n=74), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>-CB (n=55), T-LBL (n=45), PMLBL (n=24), pB-LBL (n=13) and rare or not-specified NHL subtypes (n=66) </plain></SENT>
<SENT sid="4" pm="."><plain>The 5-year event-free survival (EFS) was 79±2% for adolescents compared with 85±1% for patients aged &lt;15 years (P=0.014) </plain></SENT>
<SENT sid="5" pm="."><plain>EFS was 83±7% for adolescents with T-LBL, 82±4% with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>/B-AL, 85±5% with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>-CB, 57±10% with PMLBL and 70±6% with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALCL</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>According to sex, the 5-year EFS in females versus males, respectively, was 70±5 versus 83±2% overall (P=0.004), 57±17 versus 92±6% (P=0.0036) for T-LBL patients and 71±9 versus 97±3% (P=0.0067) for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>-CB patients </plain></SENT>
<SENT sid="7" pm="."><plain>Adolescents with NHL treated according to <z:e sem="disease" ids="C0220612" disease_type="Neoplastic Process" abbrv="">pediatric NHL</z:e>-BFM protocols had an EFS of 79±2%, which is marginally inferior to that of children </plain></SENT>
<SENT sid="8" pm="."><plain>In adolescents with T-LBL and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>-CB, female sex was associated with a worse prognosis </plain></SENT>
</text></document>